AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03326869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
Study NCT03326869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Raindrop Near Vision Inlay
Description: The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
Study NCT03043846 — intervention group
Intervention type: OTHER
Intervention: Follow-up every 3 months during 1 year (data collection in eCRF)
Study NCT03043846 — intervention group
Intervention type: OTHER
Intervention: Follow-up every month to follow the pre-defined strategy
Study NCT02420795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given PO
Study NCT02420795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02420795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02354092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic for tenaculum placement
Description: 2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
Study NCT02354092 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Local anesthetic for tenaculum placement
Description: 2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
Study NCT02354092 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions
Study NCT02354092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracervical Block
Description: 18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
Study NCT02354092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dilator Placement
Description: Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference~Drugs:~Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.~Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter.
Study NCT02354092 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dilator Placement
Description: Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference~Drugs:~Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.~Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter.
Study NCT02354092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-procedural assessment
Description: 15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
Study NCT02354092 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Post-procedural assessment
Description: 15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
Study NCT02354092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preprocedural pain control
Description: 800 mg Ibuprofen taken before dilator placement
Study NCT02354092 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Preprocedural pain control
Description: 800 mg Ibuprofen taken before dilator placement
Study NCT01630941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
Study NCT01630941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: denosumab
Description: Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
Study NCT03716336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic exercise
Description: aerobic exercise were performed on treadmill. For 20 minutes. All patients in both groups (A,B) had attended the program of a resistance exercises and followed by aerobic exercise for 8 weeks in form of 20 minutes walking on the treadmill without inclination.
Study NCT02955108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Distractive Auditory Stimuli
Description: Participants will wear headphones with no music playing
Study NCT03017339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Exercise
Study NCT03017339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional Exercise
Study NCT03017339 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Study NCT03017339 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Low Level Laser Therapy
Description: Low Level Laser Therapy with the device off
Study NCT03038971 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Dose Level 1
Description: Short and Tall Ragweed Mix
Study NCT03038971 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Dose Level 2
Description: Short and Tall Ragweed Mix
Study NCT03038971 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Description: Saline with 0.4% Phenol
Study NCT03578926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A toric lens
Description: contact lens
Study NCT03578926 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric lens
Description: contact lens
Study NCT03350971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality training
Description: training with Wii games, ergometer exercise, ambulation, standing exercises
Study NCT03350971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: chest physical therapy exercises
Study NCT03563755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: CBM-Attention (CBM-A) will be used with the aim of ameliorating negative cognitive biases in attention by redirecting attention towards positive social stimuli (accepting faces). Similarly CBM-Interpretation (CBM-I) will be used to ameliorate negative interpretation bias, by reinforcing benign outcomes of ambiguous social scenarios. Implementation intentions will be used to guide participants in planning new ways to face difficult social situations involving the risk of social rejection/criticism. Participants will continue to receive their usual treatment.
Study NCT01971671 — intervention group
Intervention type: OTHER
Intervention: no intervention.
Study NCT00393991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/formoterol fumarate 100/10
Description: FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT02577367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Administer Levothyroxine
Study NCT02577367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Administer Levothyroxine
Study NCT04629638 — intervention group
Intervention type: OTHER
Intervention: Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores
Description: The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.
Study NCT01719016 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac PET, Coronary catheterization
Description: Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:~1. N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress~2. Lexiscan - stress agent for PET scan~Patients would also undergo Coronary catheterization including the following drug administration and device usage:~1. Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).~2. Adenosine - stress agent during catheterization, 140 ug/Kg/min
Study NCT00393991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 100
Description: Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT00393991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol fumarate 10
Description: Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT02653313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parvovirus H-1 (H-1PV)
Description: Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu.
Study NCT03209362 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SI-613
Description: SI-613 will be repeated intra-articularly administered.
Study NCT03209362 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be repeated intra-articularly administered.
Study NCT02382757 — intervention group
Intervention type: DRUG
Intervention: insulin human
Description: Children will receive conventional treatment with human insulin according to standard medical practice.
Study NCT02840513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone app/CO self-monitoring
Description: Smartphone app and carbon monoxide self-monitoring (personal device)
Study NCT04381572 — intervention group
Intervention type: BEHAVIORAL
Intervention: High fidelity simulation training
Description: At the beginning of scheduled classes in the simulation center, students were placed sitting at rest for 30 min. In each team a leader was chosen. Other team members were also assigned detailed functions. Before starting the scenario, participants were oriented for 10 -15 minutes by a physician instructor about the simulation room setup and manikin features. The simulated scenarios were performed using a high fidelity computer-based manikin simulator, with the possibility of remote control of vital signs. All medications and equipment required during the clinical scenarios were available. The scenario used was prepared and validated by experienced simulation instructors. All student groups were given the same standardized scenario.
Study NCT01313078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated L-Asparaginase
Description: Pegaspargase 2000 IU/m\^2 intramuscular or intravenously every 2 weeks
Study NCT05369624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)
Description: The strength training program included upper and lower limb exercises, initially with no weights but progressively adding weights once a week depending on symptoms, in 2 sets with 6-8 repetitions, for at least 5 days a week. The exercises recommended were the 'hanger' (which exercises the latissimus dorsi muscle), 'butterfly' (pectoralis major muscle), 'neck press' (triceps brachii and deltoids), leg flexion (biceps femoris and gastrocnemius) and leg extension (quadriceps femoris).~As resistance training, patients could choose between walking or cycling 3 to 5 days per week, for at least 20 minutes, increasing the duration of the exercise weekly, depending on their symptoms
Study NCT00848770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)
Description: Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min.
Study NCT00848770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol, NPS or NOR
Description: We use one of the three drug to manipulate the systolic arterial pressure
Study NCT00848770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: manipulation of SAP
Description: Esmolol or NPS or NOR
Study NCT03073213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered as subcutaneous (SC) injection
Study NCT03035344 — intervention group
Intervention type: OTHER
Intervention: Metabolome study
Description: Metabolome study in ALL patients compared to healthy controls
Study NCT01501864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Support Intervention
Description: Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
Study NCT00727766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Study NCT03716336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: diet restriction
Description: All participants in both groups (A,B) were instructed to follow a moderate restricted diet limited to (1800-2000) kcal/ day under supervision of a certified dietician. The diet contained: Protein and fibers: 20% carbohydrate: 50-60%, fat: low 20%.
Study NCT01222039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.
Description: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
Study NCT01222039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.
Description: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
Study NCT02489695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: axitinib 10mg twice a day
Study NCT01149707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR 0110 Rectal Enema 250 mg
Description: PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
Study NCT01149707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR 0110 Rectal Enema 500 mg
Description: PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
Study NCT01149707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR 0110 Rectal Enema 1000 mg
Description: PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
Study NCT01149707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Enema
Description: Placebo Enema, once-daily, intrarectally
Study NCT02250430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204
Description: Applied topically twice a day on days 1, 2 and 3 to left and right cheeks
Study NCT04616339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-06882961 100 mg
Description: PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)
Study NCT04616339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 100 mg
Description: PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)
Study NCT03573505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00011
Description: Administered as specified in the treatment arm.
Study NCT03573505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT03666559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Chemotherapy
Study NCT01214915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide Hydrochloride
Description: Subjects will be started at 1.0 mg per day and titrated as necessary.
Study NCT03358745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal, bread/butter as starter
Description: Reference lunch. Bread and butter are eaten during the first 15 min. Soup, cheese and salad are eaten within the following 15 min.
Study NCT03358745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal with soup as starter
Description: Lunch meal in which soup is eaten during the first 15 min. Bread, butter, cheese and salad are eaten within the following 15 min.
Study NCT03358745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal with cheese as starter
Description: Lunch meal in which cheese is eaten during the first 15 min. Bread, butter, soup and salad are eaten within the following 15 min.
Study NCT03358745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal with salad as starter
Description: Lunch meal in which salad is eaten during the first 15 min. Bread, butter, soup and cheese are eaten within the following 15 min.
Study NCT01549106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
Study NCT01549106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
Study NCT01996332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg/day until progressive disease or unacceptable toxicity
Study NCT01439750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose
Study NCT01439750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).
Study NCT01439750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
Study NCT01909830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A : Gemcitabine + Pemetrexed
Description: Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days.